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Abstract
Background: Krabbe disease (KD) or globoid cell leukodystrophy is an autosomal recessive lysosomal disorder,
which affects metabolic and neurologic systems. This pathology has different forms. Infantile onset is about
85 % to 90 % of individuals with Krabbe disease. Disorder’s onset is characterized, in early childhood, by
hyperirritability, psychomotor deterioration associated to episodes of fever. To date, all reported cases have
been attributed to mutations in galactosylceramidase gene (GALC gene) that encodes an enzyme which
degrades galactosyl-sphingolipids (galactosylceramide, psychosine), essential in myelin production. A child
compounded with two new mutations in the GALC gene was detected.
Case presentation: An eleven month old male child of Moroccan origin presented to our genetic
consultation with severe symptoms that included hypotonia, fever, vision loss and feeding difficulties. He was
suffering from the 4th month of life. Krabbe disease was suspected. Galactocerebrosidase deficiency was confirmed by
biochemical analysis. DNA sequencing revealed a novel heterozygous compound mutation in GALC gene. The child
was compounded with two mutations c.860G > A; p.Cys287Tyr and c.1622G > A; p.Trp541*.
Conclusion: These new mutations could affect GALC structure and therefore its function. The identification of these
mutations and their associated phenotypes are important to predict the prognosis and to confer to families an
adequate genetic counseling.
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Background
Krabbe disease (KD) (also known as globoid cell
leucodystrophy GCL OMIM #245200) is a rare inherited
metabolic and neurodegenerative disease, which is
pathologically not completely elucidated. This autosomal
recessive lysosomal disorder affects the white matter of
the central and peripheral nervous systems. This is the
result of deficiency of the lysosomal enzyme beta
galactocerebrosidase (galactosylceramidase, GALC) or, in
very few cases, it is due to lack of activin saposin A
(sphingolipid activator protein) [1–3]. The deficiency of
GALC impairs the degradation of a major myelin lipid,
galactocerebroside and that of a parent cytotoxic com-
pound, galactosylsphingosine also called psychosine [4].
The excess of galactosylceramide elicits the formation
of multinucleated macrophages, the globoid cells.
Progressive accumulation of psychosine can explain
the prominent death of oligodendrocytes and myelin-
ation arrest, and contributes to progressive demyelin-
ation [5].
In 1916, Danish Neurologist Knud Krabbe described
for the first time a globoid cell leucodystrophy in three
families [6]. The prevalence of the disease is today
evaluated at approximatively 1/100000 births with wide
variation between countries.
Krabbe disease forms vary in age of onset and clin-
ical course. The typical infantile form is a severe,
rapidly progressive and demyelinating disease. First
symptoms appear before the age of 6 months including
hyperirritability, stiffness, hyperactive reflexes and
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episodes of elevated temperature followed by psycho-
motor deterioration, seizures, spasticity, and vision loss.
However, the clinical outcome is most variable in late
onset (i.e. juvenile and adult forms of globoid cell
leucodystrophy). As a matter of fact, muscle weakness,
vision loss and arrest of intellectual development are
consistently observed [2, 7].
All forms are caused by mutations in the GALC
gene. This gene, located on chromosome 14q31, en-
codes for the beta galactocerebrosidase protein, which
has a hydrolase function which is critical for glyco-
sphingolipid catabolism. More than 130 mutations
have been cataloged in Human Gene Mutation
Database (HGMD) so far, at least 128 of which being
reported as the cause of KD.
According to our extensive literature review, and
to the best of our knowledge, this is the first case of
KD to be reported in Morocco. We describe there-
fore the first identification of GALC mutation in a
Moroccan family.
Case presentation
An eleven month old male child, from northern
Morocco, born to unrelated parents was referred to our
medical genetics consultation with low level of galacto-
cerebrosidase; molecular analysis was necessary to con-
firm the diagnosis of Krabbe disease.
The pregnancy had been medically followed, and no
complications were reported. Weight at birth was
3300 g; the mother presenting no history of drug
ingestion nor phytotherapy. There was no family history
of congenital anomalies. The infant was the unique to a
24 years old mother and 41 years old father.
On evaluation, both of parents were found normal.
From birth to 4 month, the child had a normal develop-
ment and normal feeding. From then, his development
plateaued and rapidly regressed. Simultaneously, the
child presented episodes of fever and pulmonary
infection. The parents observed that the infant was very
irritable. Medical consultation revealed a generalized
hypertonia, increased deep tendon reflexes and arching.
Gradually, the patient gradually lost mobility of his
members. Since then, he presents a generalized hypotonia.
Hearing appeared normal, and vision was lost. This symp-
tomatology prompted the pediatric neurologist to require
galactocerebrosidase level. The result revealed a subnor-
mal level 0,3 nmol/mg protein per h, with normal values
being > 0.7 nmol/mg protein per h. These findings sug-
gested a molecular analysis of GALC gene. Genomic DNA
for the 3 family members was extracted from peripheral
blood leukocytes with a Qiagen kit according to the
manufacturer’s instructions (QIAGEN, Germany). The
quality and quantity of the DNA were checked by
A260/A280 using a Nanodrop spectrophotometer
(Nanodrop Technologies).
Fig. 1 DNA sequencing of the patient showed two novel GALC gene mutations, c.860G>A inherited from his mother and c.1622G>A inherited
from his father
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The clinical data collection and genomic analysis was
approved by the institutional ethics committee, and the
two parents provided their written informed consent.
The general condition of our patient worsened in-
creasingly. A gastrostomy tube was placed due to feed-
ing problems. The child became progressively unable to
manage his oral secretions and succumbed to aspiration
pneumonia at 14 months of age.
Discussion
The major form observed in Krabbe Disease is the infantile
form (85–90 %), characterized by rapidly progressive neuro-
logic deterioration and death before the age of two [8].
Children with such form appear to be healthy for the first
few months of life but show extreme irritability, hyper-
sensitivity to the external environment, stiffness of the
limbs, and episodic fever with no apparent reasons. The
psychomotor regression (hypertonicity, extended and
crossed legs, flexed arms and backward head) progresses to
a decerebrate posture with no voluntary movement [2]. The
onset of symptoms and clinical course can differ even
among siblings. The late infantile form (onset from 7months
to 12 months) and the juvenile form (onset from 1 to
10 years age) are characterized by spastic tetraparesis, cere-
bellar ataxia, optic atrophy, mental retardation and cognitive
decline. Onset may also occur after 20 years in the adult
form. Some individuals may remain stable for long periods,
while others show a continuous decline in vegetative state
and die. Especially in the adult phenotype, no clear
genotype-phenotype relationship is demonstrated [2, 5].
Galactocerebrosidase (GALC) enzyme activity deficiency
is observed in almost all cases of Krabbe disease [9]. In the
literature, no consistent correlation has been observed
between residual GALC enzyme activity measured in
leukocytes or cultured skin fibroblasts, and age of onset or
disease course [8, 10].
Different kinds of mutations have been described such as
missense/nonsense, small or gross deletion, splicing, inser-
tions and duplications [2]. Many different mutations affect-
ing each of the 17 exons have been reported; the majority of
which are missense mutations leading to the infant form of
Krabbe disease [8]. A 30-kb deletion, accounts for approxi-
mately 35 % of mutant alleles in individuals of Europe and
the USA [11, 12]. This large deletion appears in the homozy-
gous state or in the compound heterozygous state along with
another mutation known to cause infantile Krabbe disease.
In our clinical case, The onset of the disease was early in
the 4th months of life. The disease’s evolution has been so
fast that when we examined the patient on the 5th month,
he was entirely hypotonic and already experienced feeding
difficulty. Proband’s GALC enzyme activity was slightly
decreased. This evolution is compatible with infantile
form, which motivated us to seek the deletion of 30Kb by
real time PCR. Once we observed that there was no such
deletion, we opted for the complete sequencing of the
gene. This method revealed that our patient was het-
erozygous compound for the mutations c.860G > A
(p.Cys287Tyr) and c.1622G > A (p.Trp541*) (Fig.1).
The first mutation is a single nucleotide substitution
(c.860G > A) in exon 8 of the GALC gene. The result
showed a substitution of cysteine at position 287 to tyro-
sine (p.Cys287Tyr). The cysteine in that position is main-
tained in the 7 species reported in Multiz Alignment and
Conservation of the UCSC Genome Browser. PolyPhen
and SIFT predicted that this substitution was respectively
“probably damaging” (with score of 0.999) and “deleteri-
ous” (with score of 0.01). This mutation was found in the
proband’s mother for which she was heterozygous.
The second novel mutation c.1622G >A (p.Trp541*)
found in our patient is also a single nucleotide substitution
in exon 14 which causes a premature termination of the
GALC protein. The child inherited this mutation from his
father who was heterozygous for the mutation c.1622G >A.
It has been noted that usually GALC mutations in the
infantile form occurred in the central domain, while in the
adult form the N- or C-terminus is mutated [2, 13, 14].
More so, some mutations clearly result in the infantile
type if found in homozygous state or in compound het-
erozygous state with another severe mutation, though it
is difficult to predict the phenotype of novel mutations
or mutations found in apparent heterozygous state.
Some common polymorphisms influence enzyme ac-
tivity and may be responsible for a pseudodeficiency
state, particularly when in compound heterozygosity
with disease-causing allele [12].
A high frequency of polymorphic changes on apparent
disease-causing alleles complicates the interpretation of
the effects of mutations.
Although our patient was a compound heterozygote
for the disease, he presented a slightly decreased level of
galactocerebrosidase.
Molecular analysis of the proband has allowed for an
appropriate genetic counseling for the family.
Conclusion
We presented in this paper the first identification of a
GALC mutation in a Moroccan family. It is a novel
double heterozygous compound mutation in a Moroccan
child, who presented infantile KD form with decreased
GALC enzyme activity. These mutations may help to
enrich the GALC pathogenic mutation database and
increase public awareness of Krabbe disease in Morocco.
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